Ntagi
- All
- News
- Videos
-
India Should Keep Close Vigil On China's COVID-19 Rise: Covid Panel Chief
Amid the rising COVID cases in China, a top Indian health expert on Tuesday cautioned the people while asking them to keep a close vigil on the situation in the country.
-
Vaccine Against Cervical Cancer To Be In Immunisation Programme By Mid-2023
India would be in a position to roll out the indigenously developed Human Papillomavirus Vaccine (HPV) against cervical cancer for girls in the age group of 9-14 under the National Immunisation Programme by mid-2023, NTAGI chairperson Dr NK Arora sai
-
Cervical Cancer Vaccine Could Be Developed In India by April-May 2023: Medical Panel Chief
The Human Papillomavirus (HPV) CERVAVAC vaccine, for the prevention of cervical cancer, is expected to arrive in India by April at the one-tenth of the cost of internationally branded vaccines in the country.
-
Gap Between 2nd Covid Jab, Booster Reduced On Immunisation Group Advice: Centre
Based on the recommendations made by the National Technical Advisory Group on Immunisation (NTAGI), the interval between the second and the precaution dose of Covid vaccines was revised from nine months to six months for all beneficiaries.
-
Vaccine Panel Endorses Booster Before 9 Months If Flying Abroad: Report
The NTAGI has recommended that those who need to travel overseas can take the precaution dose of Covid vaccine as required by the country they are travelling to, before the stipulated nine-month waiting period, sources told PTI.
-
1st Dose As Booster To Those Vaccinated With Sputnik V: Top Advisory Panel
Ending the wait for a booster for all those vaccinated with Sputnik V, the NTAGI has recommended that the first dose of the Russian COVID-19 jab can be administered as the precaution dose, official sources told PTI on Saturday.
-
Immunisation Panel Approves Covovax Vaccine For 12-17 Age Group: Report
National Technical Advisory Group on Immunisation (NTAGI) on Friday approved Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17, said sources.
-
COVID-19 Working Group To Review Data For Covovax Vaccine On Friday: Report
The COVID-19 working group of the National Technical Advisory on Immunisation (NTAGI) will be reviewing the data of Serum Institute of India's vaccine - Covovax for use for children and adults, on April 1, sources said today.
-
Covishield Dose Gap Reduced To 8-16 Weeks From 12-16
India's apex body on immunisation NTAGI has recommended administering the second dose of COVID-19 vaccine Covishield between eight and 16 weeks after the first dose.
-
Vaccination For 12-14-Year-Olds Likely From March, Says Covid Panel Chief
India will likely begin inoculating children in the 12-14 age groups against Covid from March as the 15-18 population will mostly be fully vaccinated by then, Dr NK Arora, Chairman of the COVID-19 working group NTAGI, said today.
-
Anti-Covid Pill Shouldn't Be Given To Younger Population: Covid Panel Head
Molnupiravir used in treatment of Covid should not be administered to younger population as it adversely affects their reproductive system, said Dr NK Arora, Chairman of Covid Working Group of National Technical Advisory Group on Immunisation (NTAGI)
-
Covaxin Showed Good Response In Children During Trials: Covid Panel Chief
Covaxin has shown that it has a very good immune response in children in trials, Chairman of India's COVID-19 Working Group of the National Technical Advisory Group on Immunisation (NTAGI) Dr NK Arora said on Sunday.
-
Expert Panel Deliberating On Vaccinating Children Against Covid: Centre
The National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) and the National Technical Advisory Group on Immunization (NTAGI) are deliberating and considering scientific evidences related to vaccination of children, Rajya Sabha was info
-
Are Booster Doses Needed? Looking Into It, Centre Tells High Court
The Centre has told the Delhi High Court that the National Technical Advisory Group of Immunization (NTAGI) and National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) are deliberating and considering scientific evidence related to the
-
Expert Panel Considering Evidence On Justification Of Booster Covid Vaccine Dose: Centre
National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) and the National Technical Advisory Group on Immunisation (NTAGI) are considering scientific evidences related to justification for booster doses against Covid.
-
India Should Keep Close Vigil On China's COVID-19 Rise: Covid Panel Chief
Amid the rising COVID cases in China, a top Indian health expert on Tuesday cautioned the people while asking them to keep a close vigil on the situation in the country.
-
Vaccine Against Cervical Cancer To Be In Immunisation Programme By Mid-2023
India would be in a position to roll out the indigenously developed Human Papillomavirus Vaccine (HPV) against cervical cancer for girls in the age group of 9-14 under the National Immunisation Programme by mid-2023, NTAGI chairperson Dr NK Arora sai
-
Cervical Cancer Vaccine Could Be Developed In India by April-May 2023: Medical Panel Chief
The Human Papillomavirus (HPV) CERVAVAC vaccine, for the prevention of cervical cancer, is expected to arrive in India by April at the one-tenth of the cost of internationally branded vaccines in the country.
-
Gap Between 2nd Covid Jab, Booster Reduced On Immunisation Group Advice: Centre
Based on the recommendations made by the National Technical Advisory Group on Immunisation (NTAGI), the interval between the second and the precaution dose of Covid vaccines was revised from nine months to six months for all beneficiaries.
-
Vaccine Panel Endorses Booster Before 9 Months If Flying Abroad: Report
The NTAGI has recommended that those who need to travel overseas can take the precaution dose of Covid vaccine as required by the country they are travelling to, before the stipulated nine-month waiting period, sources told PTI.
-
1st Dose As Booster To Those Vaccinated With Sputnik V: Top Advisory Panel
Ending the wait for a booster for all those vaccinated with Sputnik V, the NTAGI has recommended that the first dose of the Russian COVID-19 jab can be administered as the precaution dose, official sources told PTI on Saturday.
-
Immunisation Panel Approves Covovax Vaccine For 12-17 Age Group: Report
National Technical Advisory Group on Immunisation (NTAGI) on Friday approved Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17, said sources.
-
COVID-19 Working Group To Review Data For Covovax Vaccine On Friday: Report
The COVID-19 working group of the National Technical Advisory on Immunisation (NTAGI) will be reviewing the data of Serum Institute of India's vaccine - Covovax for use for children and adults, on April 1, sources said today.
-
Covishield Dose Gap Reduced To 8-16 Weeks From 12-16
India's apex body on immunisation NTAGI has recommended administering the second dose of COVID-19 vaccine Covishield between eight and 16 weeks after the first dose.
-
Vaccination For 12-14-Year-Olds Likely From March, Says Covid Panel Chief
India will likely begin inoculating children in the 12-14 age groups against Covid from March as the 15-18 population will mostly be fully vaccinated by then, Dr NK Arora, Chairman of the COVID-19 working group NTAGI, said today.
-
Anti-Covid Pill Shouldn't Be Given To Younger Population: Covid Panel Head
Molnupiravir used in treatment of Covid should not be administered to younger population as it adversely affects their reproductive system, said Dr NK Arora, Chairman of Covid Working Group of National Technical Advisory Group on Immunisation (NTAGI)
-
Covaxin Showed Good Response In Children During Trials: Covid Panel Chief
Covaxin has shown that it has a very good immune response in children in trials, Chairman of India's COVID-19 Working Group of the National Technical Advisory Group on Immunisation (NTAGI) Dr NK Arora said on Sunday.
-
Expert Panel Deliberating On Vaccinating Children Against Covid: Centre
The National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) and the National Technical Advisory Group on Immunization (NTAGI) are deliberating and considering scientific evidences related to vaccination of children, Rajya Sabha was info
-
Are Booster Doses Needed? Looking Into It, Centre Tells High Court
The Centre has told the Delhi High Court that the National Technical Advisory Group of Immunization (NTAGI) and National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) are deliberating and considering scientific evidence related to the
-
Expert Panel Considering Evidence On Justification Of Booster Covid Vaccine Dose: Centre
National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) and the National Technical Advisory Group on Immunisation (NTAGI) are considering scientific evidences related to justification for booster doses against Covid.
